Vaccine Trials

“A phase I/II clinical trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine boosted by a multiclade HIV-1 recombinant adenovirus-5 vector vaccine in HIV uninfected adult volunteers in East Africa”

Purpose

The objectives of the study were to evaluate the safety and immunogenicity of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP). The vaccine was provided by the NIH Vaccine Research Center (VRC) consisting of a multiclade A, B and C HIV DNA prime (VRC-HIVDNA016-00-VP) boosted with a multiclade A, B and C recombinant Adenovirus type 5 vector (VRC-HIVADV014-00-VP).

Team: Leonard Maboko (Principal Investigator), Mirjam Schunk, Arne Kroidl (Clinical Research Coordinator)

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya RT @IHIEurope: Interested IHI’s forthcoming calls for proposals? The draft topic texts are already online! ➡️Check them out: https://t.co/
20hreplyretweetfavorite
NIMRMbeya RT @EDCTP: At EDCTP, it's #AfricaDay every day 🙌 🧐Want to know the impact of our work in Africa? 📊Read all about it in our 'Summary of a…
20hreplyretweetfavorite
NIMRMbeya On this #Africaday2022 we pledge our commitment to undertake quality and ethical research for improved health care… https://t.co/kWSsPgbEB0
NIMRMbeya RT @mrema_lucy: Bringing the Diabetes World together! I am happy to be a delegate in the 82nd Scientific Session of the American Diabetes…
NIMRMbeya Your work is appreciated Prof. Karim Manji 👏👏 https://t.co/gThLCW0ZbH
© 2017 NIMR - Mbeya Medical Research Center